Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR3 | P49019 | 3/20 | 0.40 |
| ▸ | LMNA | P02545 | 5/20 | 0.35 |
| ▸ | MAPT | P10636 | 3/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.32 |
| ▸ | HTT | P42858 | 2/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.32 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.32 |
| ▸ | OGA | O60502 | 4/20 | 0.32 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | PKM | P14618 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4947807 | 0.90 | HCAR3 (0.41) | HCAR3LMNAMAPTGAAHPGD | |
| SCHEMBL691192 | 0.89 | HCAR3 (0.40) | HCAR3LMNAMAPTGAAHPGD | |
| SCHEMBL691769 | 0.84 | HCAR3 (0.44) | HCAR3MAPTALDH1A1 | |
| SCHEMBL2691580 | 0.78 | LMNA (0.42) | LMNAMAPTGAAHPGDOGA | |
| SCHEMBL2689454 | 0.77 | LMNA (0.41) | LMNAMAPTGAAHPGDSMN1; SMN2 | |
| SCHEMBL4759337 | 0.76 | LMNA (0.38) | HCAR3LMNAMAPTGAAHPGD | |
| SCHEMBL4759320 | 0.75 | LMNA (0.40) | LMNAMAPTGAAHPGDMAPK1 | |
| SCHEMBL1770533 | 0.74 | HCAR3 (0.38) | HCAR3LMNAMAPTHPGDTSHR | |
| SCHEMBL4949067 | 0.74 | LMNA (0.37) | LMNAMAPTGAAHPGDSMN1; SMN2 | |
| SCHEMBL1770530 | 0.74 | HCAR3 (0.41) | HCAR3LMNAMAPTGAAHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9243000-B2 | Thia-triaza-indacenes | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2016-01-26 | — | — | US | disclosed |
| EP-2421872-B1 | THIA-TRIAZA-AS-INDACENES AS PI3-KINASES INHIBITORS FOR THE TREATMENT OF CANCER | BOEHRINGER INGELHEIM INT (DE) | 2015-06-10 | — | — | EP | disclosed |
| US-20120108618-A1 | THIA-TRIAZA-INDACENES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-05-03 | — | — | US | disclosed |
| WO-2010122091-A1 | THIA-TRIAZA-AS-INDACENES AS PI3-KINASES INHIBITORS FOR THE TREATMENT OF CANCER | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-10-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120108618-A1 | THIA-TRIAZA-INDACENES | CCNA1, MKI67, CCNT1 | HCAR3 4031/4885LMNA 1287/4885MAPT 1921/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.